Nesiritide in the initial management of acute decompensated congestive heart failure

What Was Tested

Researchers studied BNP (Nesiritide) in this randomized controlled trial publication.

In the era of evolving therapy for heart failure (HF), optimal medical therapy has become challenging.

Nesiritide is being used for HF therapy but its impact is still controversial.

Who Took Part

According to the abstract, 34 patients were involved.

PubMed indexes the participants as older adults, both men and women.

Prospective and randomized controlled study of 34 patients who presented to the emergency department (ED) with HF and remained symptomatic despite maximal standard therapy delivered for at least one hour.

How the Study Was Run

In design terms this was a randomized study.

The patients were allocated by chance, so the BNP (Nesiritide) group and the comparison group should start out alike.

Primary endpoints included HF hospital readmission, and hospital length of stay (LOS).

Secondary endpoints included HF, cardiovascular, all-cause mortality, and adverse events.

Composite risk score was designed.

Results were analyzed using a logistic regression model and bootstrapping simulating approach.

What Was Measured

PubMed files the paper under topics including Comorbidity, Emergency Service, Hospital, Heart Failure, Length of Stay, Logistic Models, Natriuretic Agents and Natriuretic Peptide, Brain.

What This Means in Plain Language

The paper is a randomized study of BNP (Nesiritide) in 34 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2008 (Connecticut medicine), a journal based in United States.

More context: the BNP (Nesiritide) compound page, all human trials.